HomeCompareEMPYF vs JNJ

EMPYF vs JNJ: Dividend Comparison 2026

EMPYF yields 293.04% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMPYF wins by $1293.59M in total portfolio value
10 years
EMPYF
EMPYF
● Live price
293.04%
Share price
$0.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1293.61M
Annual income
$774,021,181.48
Full EMPYF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EMPYF vs JNJ

📍 EMPYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMPYFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMPYF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMPYF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMPYF
Annual income on $10K today (after 15% tax)
$24,908.42/yr
After 10yr DRIP, annual income (after tax)
$657,918,004.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, EMPYF beats the other by $657,917,300.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMPYF + JNJ for your $10,000?

EMPYF: 50%JNJ: 50%
100% JNJ50/50100% EMPYF
Portfolio after 10yr
$646.82M
Annual income
$387,011,004.63/yr
Blended yield
59.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EMPYF
No analyst data
Altman Z
8.7
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMPYF buys
0
JNJ buys
0
No recent congressional trades found for EMPYF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMPYFJNJ
Forward yield293.04%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$1293.61M$20.0K
Annual income after 10y$774,021,181.48$827.78
Total dividends collected$1241.10M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMPYF vs JNJ ($10,000, DRIP)

YearEMPYF PortfolioEMPYF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$40,004$29,304.03$10,676$355.77+$29.3KEMPYF
2$152,363$109,558.81$11,407$389.39+$141.0KEMPYF
3$553,006$389,977.58$12,198$426.53+$540.8KEMPYF
4$1,914,552$1,322,835.81$13,056$467.62+$1.90MEMPYF
5$6,328,726$4,280,154.80$13,987$513.12+$6.31MEMPYF
6$19,994,576$13,222,839.70$14,998$563.56+$19.98MEMPYF
7$60,436,630$39,042,433.57$16,098$619.52+$60.42MEMPYF
8$174,958,464$110,291,269.98$17,295$681.69+$174.94MEMPYF
9$485,600,924$298,395,367.51$18,599$750.82+$485.58MEMPYF
10$1,293,614,171$774,021,181.48$20,022$827.78+$1293.59MEMPYF

EMPYF vs JNJ: Complete Analysis 2026

EMPYFStock

Empress Royalty Corp. acquires royalty and streaming interests in precious metal mines and mining projects. The company has a portfolio of 17 precious metals royalties in Canada. It has net smelter return royalty interests in the Pinos Royalty and McLeroy-Pinos Royalty in the Pinos gold-silver project in Mexico. The company was incorporated in 2020 and is headquartered in White Rock, Canada.

Full EMPYF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EMPYF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMPYF vs SCHDEMPYF vs JEPIEMPYF vs OEMPYF vs KOEMPYF vs MAINEMPYF vs ABBVEMPYF vs MRKEMPYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.